Rob Maguire, PhD

Rob Maguire is a medicinal chemist focused on the design and development of PDCs for the treatment of cancer.  Following completion of his PhD at the University of Manchester and post-doctoral research in Germany and Canada, Rob started his career with Pfizer medicinal chemistry in Sandwich, UK.  Rob joined Cybrexa in October 2019 and led the chemistry team for CBX-12 through pre-clinical studies to late Phase 1.  His work is now focused on developing new expressions of the Alphalex™ platform to broaden the reach of this powerful PDC technology in the treatment of cancer.